Table 1.
Baseline demographics of patient population (n = 121, entire cohort)
| Weak target tumour enhancement (n = 74) |
Strong target tumour enhancement (n = 47) |
p value* | |
|---|---|---|---|
| Age | |||
| < 65 years | 40 (54.1%) | 24 (51.1%) | p = 0.75 |
| ≥ 65 years | 34 (45.9%) | 23 (48.9%) | |
| Sex | |||
| Male | 43 (58.1%) | 27 (57.4%) | p = 0.94 |
| Female | 31 (41.9%) | 20 (42.6%) | |
| Clinical risk score | |||
| < 3 | 52 (76.5%) | 34 (77.3%) | p = 0.92 |
| ≥ 3 | 16 (23.5%) | 10 (22.7%) | |
| Number of tumours | |||
| = 1 tumour | 36 (48.6%) | 17 (36.2%) | p = 0.18 |
| > 1 tumour | 38 (51.4%) | 30 (63.8%) | |
| Tumour size | |||
| < 5 cm | 55 (74.3%) | 43 (91.5%) | p = 0.019* |
| ≥ 5 cm | 19 (25.7%) | 4 (8.5%) | |
| Time from diagnosis of primary to diagnosis of metastasis | |||
| ≤ 12 months | 30 (40.5%) | 13 (27.7%) | p = 0.149 |
| > 12 months | 44 (59.5%) | 34 (72.3%) | |
| Number of positive lymph nodes | |||
| < 5 nodes positive | 53 (73.6%) | 36 (76.6%) | p = 0.71 |
| ≥ 5 nodes positive | 19 (26.4%) | 11 (23.4%) | |
| Data not available | 2 | 0 | |
| Preoperative CEA level | |||
| < 200 ng/ml | 60 (95.2%) | 43 (95.6%) | p = 0.94 |
| ≥ 200 ng/ml | 3 (4.8%) | 2 (4.4%) | |
| Data not available | 11 | 2 | |
| Magnet | |||
| 1.5 T | 45 (60.8%) | 30 (63.8%) | p = 0.74 |
| 3.0 T | 29 (39.2%) | 17 (36.2%) | |